Electromed, Inc. ELMD
We take great care to ensure that the data presented and summarized in this overview for Electromed, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELMD
View all-
Punch & Associates Investment Management, Inc. Edina, MN374KShares$5.53 Million0.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA367KShares$5.43 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX283KShares$4.18 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA214KShares$3.17 Million0.01% of portfolio
-
Mario Gabelli Gamco Investors, Inc. Et Al | Rye, Ny111KShares$1.65 Million0.02% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX107KShares$1.59 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny98.3KShares$1.45 Million0.0% of portfolio
-
Royal Bank Of Canada Toronto, A694.4KShares$1.4 Million0.0% of portfolio
-
Hunter Associates Investment Management LLC Pittsburgh, PA86.2KShares$1.27 Million0.23% of portfolio
-
Geode Capital Management, LLC Boston, MA68.3KShares$1.01 Million0.0% of portfolio
Latest Institutional Activity in ELMD
Top Purchases
Top Sells
About ELMD
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care and institutional markets for patients with bronchiectasis, cystic fibrosis, and neuromuscular diseases. It markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Insider Transactions at ELMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 01
2024
|
James L. Cunniff CEO and President |
BUY
Open market or private purchase
|
Direct |
9,000
+47.37%
|
$135,000
$15.25 P/Share
|
Dec 14
2023
|
Andrew Summers Director |
BUY
Open market or private purchase
|
Indirect |
28,797
+7.56%
|
$287,970
$10.5 P/Share
|
Dec 01
2023
|
Andrea M. Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+20.0%
|
-
|
Dec 01
2023
|
Joseph L. Galatowitsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+25.0%
|
-
|
Dec 01
2023
|
Andrew Summers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+33.33%
|
-
|
Dec 01
2023
|
Kathleen A Tune Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+25.0%
|
-
|
Dec 01
2023
|
Kathleen Skarvan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+2.02%
|
-
|
Dec 01
2023
|
Gregory Fluet Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.67%
|
-
|
Dec 01
2023
|
Stan K. Erickson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+8.38%
|
-
|
Nov 21
2023
|
James L. Cunniff CEO and President |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$10,000
$10.56 P/Share
|
Jul 12
2023
|
Kathleen Skarvan Director |
SELL
Open market or private sale
|
Direct |
1,107
-0.77%
|
$11,070
$10.83 P/Share
|
Jul 01
2023
|
Bradley M. Nagel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,600
+36.26%
|
-
|
Feb 27
2023
|
Kathleen Skarvan Director |
SELL
Bona fide gift
|
Direct |
40,185
-21.87%
|
-
|
Feb 27
2023
|
Kathleen Skarvan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
24,815
-11.9%
|
$322,595
$13.5 P/Share
|
Feb 27
2023
|
Kathleen Skarvan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+13.99%
|
$65,000
$1.36 P/Share
|
Dec 01
2022
|
Andrea M. Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+25.0%
|
-
|
Dec 01
2022
|
Kathleen A Tune Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+33.33%
|
-
|
Dec 01
2022
|
Andrew Summers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+50.0%
|
-
|
Dec 01
2022
|
A Jones Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+9.62%
|
-
|
Dec 01
2022
|
Joseph L. Galatowitsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+33.33%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 27.6K shares |
---|---|
Open market or private purchase | 38.8K shares |
Open market or private sale | 1.11K shares |
---|